Loading...

RCKT ROCKET PHARMACEUTICALS INC US FDA Inspections 8-K Filing

RCKT

RCKT

ROCKET PHARMACEUTICALS INC

(RCKT)

2025 8-K

Financial Results Update

FDA Application Resubmitted

Board Resignation

Management Change

Management Change

FDA Approval Lifted

Management Changes

Management Changes

Regenerative Medicine Desig...

Regulatory Compliance

Product Expansion

Financial Statements

Management Appointment

Financial Results

Management Change

Danon Disease Update

Financial Results

Board Appointment

Financial Results

Annual Meeting Approval

Financial Results

Appointment of CFO

Financial Results Announcement

FDA Review Period Extended

Appointment of R. Keith Woo...

Underwriting Agreement

Amendment to Sales Agreement

Updates on Danon Disease Pr...

Annual Meeting of Stockholders

Management Changes

Financial Results Announcement

FDA Designation for Gene Th...

External Links:

On July 17, 2025, Rocket Pharmaceuticals, Inc. announced that the U.S. FDA granted RMAT designation for RP-A601, a gene therapy for treating PKP2-arrhythmogenic cardiomyopathy.

AI Assistant

ROCKET PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.